ABCL vs. ALKS, PRGO, CRNX, CORT, AXSM, RARE, PBH, HCM, MRUS, and ARWR
Should you be buying AbCellera Biologics stock or one of its competitors? The main competitors of AbCellera Biologics include Alkermes (ALKS), Perrigo (PRGO), Crinetics Pharmaceuticals (CRNX), Corcept Therapeutics (CORT), Axsome Therapeutics (AXSM), Ultragenyx Pharmaceutical (RARE), Prestige Consumer Healthcare (PBH), HUTCHMED (HCM), Merus (MRUS), and Arrowhead Pharmaceuticals (ARWR). These companies are all part of the "pharmaceutical preparations" industry.
Alkermes (NASDAQ:ALKS) and AbCellera Biologics (NASDAQ:ABCL) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, profitability, dividends, media sentiment, community ranking, risk, analyst recommendations, earnings and institutional ownership.
95.2% of Alkermes shares are owned by institutional investors. Comparatively, 61.4% of AbCellera Biologics shares are owned by institutional investors. 4.9% of Alkermes shares are owned by insiders. Comparatively, 32.5% of AbCellera Biologics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
In the previous week, Alkermes had 6 more articles in the media than AbCellera Biologics. MarketBeat recorded 7 mentions for Alkermes and 1 mentions for AbCellera Biologics. AbCellera Biologics' average media sentiment score of 1.14 beat Alkermes' score of -0.92 indicating that Alkermes is being referred to more favorably in the media.
Alkermes has a net margin of 25.17% compared to Alkermes' net margin of -410.47%. AbCellera Biologics' return on equity of 20.31% beat Alkermes' return on equity.
Alkermes currently has a consensus target price of $36.78, suggesting a potential upside of 52.04%. AbCellera Biologics has a consensus target price of $16.17, suggesting a potential upside of 360.59%. Given Alkermes' stronger consensus rating and higher probable upside, analysts plainly believe AbCellera Biologics is more favorable than Alkermes.
Alkermes has a beta of 0.47, indicating that its stock price is 53% less volatile than the S&P 500. Comparatively, AbCellera Biologics has a beta of 0.45, indicating that its stock price is 55% less volatile than the S&P 500.
Alkermes received 635 more outperform votes than AbCellera Biologics when rated by MarketBeat users. However, 77.27% of users gave AbCellera Biologics an outperform vote while only 70.65% of users gave Alkermes an outperform vote.
Alkermes has higher revenue and earnings than AbCellera Biologics. AbCellera Biologics is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks.
Summary
Alkermes beats AbCellera Biologics on 12 of the 18 factors compared between the two stocks.
Get AbCellera Biologics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ABCL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ABCL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
AbCellera Biologics Competitors List
Related Companies and Tools
